Abstract
Background/Aim: The evaluation of radiotherapy toxicity in oncologic IBD patients. Defining the optimal patient and treatment factors that would be able to reduce the risk to organs.
Materials and Methods: A review of all published radiotherapy trials was performed to identify the clinical and treatment factors of inflammatory bowel disease’s patients treated for different solid tumors.
Results: Overall, acute (Grade ≥ 3) gastrointestinal complications attributable to RT ranged between 20-21% of the treated patients. A late Grade ≥ 3 gastrointestinal toxicity was developed in a range between 8-29%.
Conclusion: A special attention should be given to the description of IBD location, activity status, concurrent chemotherapy, irradiation dose and technique, in order to minimize post-irradiation morbidity. It is not easy to distinguish late morbidity attributable to radiotherapy due to the IBD itself.
Keywords: Inflammatory bowel diseases, radiotherapy, toxicity.
Reviews on Recent Clinical Trials
Title:Irradiation Toxicity and Inflammatory Bowel Diseases (IBD): Review
Volume: 9 Issue: 1
Author(s): Tolia Maria, Zygogianni Anna, Kouvaris John R., Tsoukalas Nikolaos, Kokakis Ioannis, Kyrgias George, Mystakidou Kyriaki and Kouloulias Vasileios
Affiliation:
Keywords: Inflammatory bowel diseases, radiotherapy, toxicity.
Abstract: Background/Aim: The evaluation of radiotherapy toxicity in oncologic IBD patients. Defining the optimal patient and treatment factors that would be able to reduce the risk to organs.
Materials and Methods: A review of all published radiotherapy trials was performed to identify the clinical and treatment factors of inflammatory bowel disease’s patients treated for different solid tumors.
Results: Overall, acute (Grade ≥ 3) gastrointestinal complications attributable to RT ranged between 20-21% of the treated patients. A late Grade ≥ 3 gastrointestinal toxicity was developed in a range between 8-29%.
Conclusion: A special attention should be given to the description of IBD location, activity status, concurrent chemotherapy, irradiation dose and technique, in order to minimize post-irradiation morbidity. It is not easy to distinguish late morbidity attributable to radiotherapy due to the IBD itself.
Export Options
About this article
Cite this article as:
Maria Tolia, Anna Zygogianni, R. John Kouvaris, Nikolaos Tsoukalas, Ioannis Kokakis, George Kyrgias, Kyriaki Mystakidou and Vasileios Kouloulias, Irradiation Toxicity and Inflammatory Bowel Diseases (IBD): Review, Reviews on Recent Clinical Trials 2014; 9 (1) . https://dx.doi.org/10.2174/1574887109666140423123845
DOI https://dx.doi.org/10.2174/1574887109666140423123845 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Angiotensin in Obesity and Metabolic Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Rheumatoid Nodules and Lung
Current Respiratory Medicine Reviews Nitric Oxide and Cyclic GMP Signaling Pathway as a Focus for Drug Development
Current Medicinal Chemistry Update on Clinical, Pathophysiological and Therapeutic Aspects in ANCAAssociated Vasculitides
Current Drug Discovery Technologies Impact of Patient Knowledge of Hypertension Complications on Adherence to Antihypertensive Therapy
Current Hypertension Reviews Epigenetic Modulation of Myocardial Angiogenic Balance: An Emerging Therapeutic Perspective for Adult Failing Heart
Current Angiogenesis (Discontinued) Phytoestrogens and Mitochondrial Biogenesis in Breast Cancer. Influence of Estrogen Receptors Ratio
Current Pharmaceutical Design Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis
Current Pharmaceutical Design Anterior Uveitis with Negative Work-up: Giant Cell Arteritis Remains the Pet Peeve
Current Rheumatology Reviews Heat Shock Proteins - Two Sides of a Coin
Current Cardiology Reviews Pathobiology of Stent Thrombosis after Drug-Eluting Stent Implantation
Current Pharmaceutical Design Applications of FDG-PET/CT in Assessment of Vascular Infection and Inflammation
Current Molecular Imaging (Discontinued) Interleukin-5, Eosinophilic Diseases and Therapeutic Intervention
Current Drug Targets - Inflammation & Allergy Editorial: (Thematic Issue: Autoimmune diseases: What have we learned from mice?)
Current Pharmaceutical Design Hypersensitivity Reactions to Last Generation Chimeric, Umanized and Human Recombinant Monoclonal Antibodies for Therapeutic Use
Current Pharmaceutical Design Naringenin and Atherosclerosis: A Review of Literature
Current Pharmaceutical Biotechnology Dyslipidaemia Related to Insulin Resistance and Cardiovascular Disease in South Asian and West African Populations
Current Pharmaceutical Design Torsades de Pointes in Patients with Polymyalgia Rheumatica
Current Pharmaceutical Design Modern Therapeutic Strategies for Autoimmune Diseases
Current Pharmaceutical Design Spontaneous (Autoimmune) Chronic Urticaria in Children: Current Evidences, Diagnostic Pitfalls and Therapeutic Management
Recent Patents on Inflammation & Allergy Drug Discovery